Apple Q2 2026 Earnings Surge as iPhone 17 Sales Drive Record Revenue 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
Pinterest Stock Surges After Strong Q1 2026 Earnings Beat Expectations 
Meta Plans $13B AI Data Center Financing in Texas Amid Surging Big Tech Investment 
Palantir Reports Record Growth, Raises 2026 Revenue Outlook Above Expectations 
Berkshire Hathaway Q1 Earnings Jump 18% as Greg Abel Signals Disciplined Growth Strategy 
GameStop Proposes $56 Billion eBay Acquisition in Bold Strategic Move 
Anthropic’s $1.5B AI Venture with Wall Street Firms Targets Private Equity Market 
NAB First-Half Earnings Miss Forecasts Amid Rising Global Risks 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
Apple Explores Intel and Samsung Partnerships to Diversify Chip Supply Chain 
GameStop Eyes eBay Acquisition as Stock Prices Surge After Hours 
Samsung Appoints New TV Business Head Amid Rising Competition from Chinese Rivals 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
Middle East Conflict Impacts Australia and New Zealand Businesses 
Regis Resources and Vault Minerals to Merge in $10.7B Gold Deal 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
EXTON, Pa., May 03, 2018 -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, will report financial results for the first quarter ended March 31, 2018 and recent operational highlights on Thursday, May 10, 2018 before the open of the U.S. financial markets. Fibrocell will also host a conference call and webcast at 8:30 a.m. EDT on the same day to discuss its financial results and operational highlights. A question-and-answer session will follow Fibrocell’s remarks.
To participate on the live call, please dial 866-548-4713 (domestic) or +1-323-794-2093 (international), and provide the conference code 3897293 five to ten minutes before the start of the call. The conference call will also be webcast live under the investor relations section of Fibrocell's website at www.fibrocell.com/investors/events and will be archived there for 30 days following the call.
About Fibrocell
Fibrocell is an autologous cell and gene therapy company translating personalized biologics into medical breakthroughs for diseases affecting the skin and connective tissue. Fibrocell’s most advanced product candidate, FCX-007, is the subject of a Phase 1/2 clinical trial for the treatment of recessive dystrophic epidermolysis bullosa. Fibrocell is also developing FCX-013, the Company’s product candidate for the treatment of moderate to severe localized scleroderma. Fibrocell’s gene therapy portfolio is being developed in collaboration with Intrexon Corporation (NYSE:XON), a leader in synthetic biology. For more information, visit www.fibrocell.com or follow Fibrocell on Twitter at @Fibrocell.
Trademarks
Fibrocell, the Fibrocell logo, and Fibrocell Science are trademarks of Fibrocell Science, Inc. and/or its affiliates. All other names may be trademarks of their respective owners.
Investor & Media Relations Contact:
Karen Casey
484-713-6133
[email protected]
